Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...
BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...
15h
TipRanks on MSNDesert Metals Ltd. Releases Interim Financial Report for 2024Desert Metals Ltd. ( ($AU:DM1) ) has provided an announcement. Desert Metals Ltd. has released its interim financial report for the half year ...
BMO Capital Markets initiated coverage on Dyne Therapeutics (DYN, Financials) with an Outperform rating and a $50 price ...
4d
News-Medical.Net on MSNResearch links kidney dysfunction to muscle weakness in myotonic dystrophy type 1Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature Communications, "Analysis of human urinary extracellular ...
Thurman M. Wheeler, MD, of the Department of Neurology at Massachusetts General Hospital, is the senior author of a paper published in Nature ...
Dyne Therapeutics (DYN) stock gains premarket momentum as BMO Capital Markets issus a new Outperform rating on the company. Read more here.
Details of the presentation are as follows: Arrakis’s DM1 drug program represents a rationally designed small molecule genetic medicine directed at a pathogenic RNA to achieve reversal of ...
BMO Capital analyst Kostas Biliouris initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $50 price target The firm ...
Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that the company will present ...
A live webcast will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results